معرفی
Megan Delisle is an Assistant Professor in the Department of Surgery at the Max Rady College of Medicine, University of Manitoba, and an affiliate scientist at the Paul Albrechtsen CancerCare Manitoba Research Institute. She serves as a surgical oncologist at CancerCare Manitoba and Shared Health, dedicating equal time to clinical practice and research leadership.
Education:
- Fellowship in Complex General Surgical Oncology, University of Ottawa (2023)
- General Surgery Residency, University of Manitoba (2021)
- Doctor of Medicine, McGill University (2014)
- Master of Public Health, Harvard T.H. Chan School of Public Health (2019)
- Master of Science in Surgery, Clinician Investigator Program, University of Manitoba (2019)
Her research pioneers precision oncology implementation in real-world healthcare systems through pragmatic clinical trials and health services research. She focuses on optimizing resource utilization across the entire cancer continuum—from prevention to survivorship—by bridging methodological innovation with clinical practice translation. Her work emphasizes multidisciplinary collaboration to address systemic inefficiencies in cancer care delivery.
Scientific Awards:
- Culture Changer Champion, Canadian Federation of Medical Students (2022)
- Department of Surgery Resident and Fellow Recognition Award Nominee, University of Ottawa (2022)
- Nancie J. Mauro Graduate Scholarship in Oncology Research, University of Manitoba (2019)
- Resident Spotlight for Excellence in Research, Canadian Association of General Surgeons (2019)
- Canadian Institutes of Health Research Master’s Award (2018)
- Mindel and Tom Olenick Research Studentships in Medicine (2018)
Dr. Delisle actively mentors Master's and undergraduate students through the University of Manitoba's surgical oncology research programs. Her work is embedded within the Health Services Research Lab at the CancerCare Manitoba Research Institute, where she leads a collaborative team of clinicians, scientists, and trainees focused on scalable solutions for cancer care delivery. Current initiatives include pragmatic trials evaluating precision oncology integration and implementation science frameworks for reducing healthcare disparities.
